Arrowstreet Capital Limited Partnership Lowers Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Arrowstreet Capital Limited Partnership decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 53.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 101,961 shares of the company's stock after selling 115,691 shares during the period. Arrowstreet Capital Limited Partnership owned 0.33% of Medpace worth $33,875,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Pallas Capital Advisors LLC increased its position in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock valued at $1,086,000 after buying an additional 2,101 shares in the last quarter. Barclays PLC raised its position in shares of Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC boosted its stake in Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock worth $1,738,000 after purchasing an additional 844 shares in the last quarter. Janus Henderson Group PLC grew its position in Medpace by 10.0% during the 3rd quarter. Janus Henderson Group PLC now owns 44,118 shares of the company's stock valued at $14,722,000 after purchasing an additional 4,023 shares during the last quarter. Finally, SYM FINANCIAL Corp bought a new stake in Medpace during the 4th quarter valued at about $320,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Finally, Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $376.30.

Remove Ads

Medpace Stock Up 1.0 %

NASDAQ:MEDP traded up $2.99 on Monday, hitting $290.10. The stock had a trading volume of 777,818 shares, compared to its average volume of 309,719. Medpace Holdings, Inc. has a 52-week low of $274.02 and a 52-week high of $459.77. The stock has a market cap of $8.77 billion, a price-to-earnings ratio of 22.97, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. The business's 50-day simple moving average is $330.36 and its two-hundred day simple moving average is $336.76.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.